On January 30, Arkansas senator Tom Cotton tweeted that although he didnt know where the novel coronavirus, SARS-CoV-2, originated, he wanted to point out that "Wuhan has Chinas only biosafety level-four super laboratory that works with the worlds most deadly pathogens to include, yes, coronavirus.
He was implying, as other conspiracy theorists have continued to do, that the new virus was intentionally made and released (ignoring the fact there are many "level-four super laboratories" around the world). Politicians, including Donald Trump, continue to call SARS-CoV-2 the Chinese virus or Wuhan Virus.
But the origins of viruses, and how they come to infect humans, are almost always more complicated than a couple of evil geniuses secretly creating infectious killers. Viruses mutate constantly, playing the equivalent of a genetic slot machine until they chance upon the winning genetic sequences to allow them to jump from animals into humans, and be infectious enough to spread their genetic information far and wide.
While theres still so much uncertainty about the COVID-19 pandemichow long it will last, what treatment options might work, when a vaccine will arrive, there are actually a lot of things that we do know about the virus, through genetics and structural biologyincluding where it came from.
In a new paper in Nature Medicine, scientists from the U.S., Australia, and the U.K. analyzed the virus closelyoutlining its likely origins and exactly how and why it seems to be more infectious than previous coronaviruses, like SARS or MERS. Their research also provides a resolution to the made-in-a-lab speculation. Kristian Andersen, an associate professor of immunology and microbiology at Scripps Research, said in a press release: We can firmly determine that SARS-CoV-2 originated through natural processes."
You can tell a lot about a virus from its genomewhat kind of virus it is, and how closely related it is to viruses you already know about. The genetic sequence to SARS-CoV-2 was made available very quickly by Chinese scientists, allowing researchers all over the world to see what made the new virus tick.
Coronaviruses get their name from spikes that cover their surface that look a bit like the suns corona. Those spikes are key to how the virus infects a human cell and two integral parts of the new viruss spikes are slightly different from those of previous coronaviruses. These differences could help us understand how its spreading farther and infecting more people.
The first change is in the receptor-binding domain. This is part of the spike that binds to a human cellfor this virus it attaches to ACE-2, a cell membrane enzyme that regulates blood pressure.
We already knew that the 2003 SARS binding could bind pretty tightly to ACE-2. But in a Science paper this month, researchers using cryo-electron microscopy revealed that the new viruss spike was better. It binds to the ACE-2 receptor 10 times more tightly than a SARS virus does. This difference is made possible by small variations in structure to the receptor binding domain.
The second adaptation in the new coronavirus is a part of the spike called the cleavage site. The spike is a folded up-bundle, and it has to be cleaved, or cut, in a specific place to pop open, like releasing a spring. After being cleaved, the spike is used to grab onto a human cell.
The cleavage site is made up of small amino acid sequences that are recognized by cellular enzymes called proteases, enlisted to do the cutting. These molecular scissors are different for each coronavirus. SARS-CoV-2's cleavage site is made of amino acids that attract an enzyme called furin. Our bodies make furin in a lot of different tissues, but in particular, in the upper respiratory and lower respiratory tract.
When a virus has a cleavage site that attracts furin to do the cutting, it becomes more dangerous. To compare, influenza viruses are often cleaved and activated by enzymes called trypsin, "which are typically restricted to certain tissues and organs," said Jean Millet, a microbiologist at the Molecular Virology and Immunology unit of INRAE, located in France, who wasn't involved in the paper.
Experiments with avian influenza virus have shown that if they evolve a furin cleavage site, they become much more infectious. Having a furin cleavage site means that the virus is able to replicate more, and in different tissues. It can easily go into the lower respiratory tract. It may be one of the reasons that people develop pneumoniathough this hasnt been proven for certain.
Seeing that in the new SARS-CoV-2 when those sequences came out for the first time actually kept me up all night, said Bob Garry, an assistant professor of microbiology and immunology at Tulane University School of Medicine and co-author of the Nature paper.
These changes may be alarming, but they're also how we know this virus wasn't designed in the lab. Simply put, the adaptationsspecifically the binding to ACE2are just too good for a human to have come up with it.
Computer programs that scientists use to model the interactions between a virus's spike and ACE-2 dont predict that the receptor SARS-CoV-2 has would work very well. And yet, it doesas Wrapp found, 10 times better. Its an indication that the alterations in the binding were selected for through natural selection, not genetic engineering.
You couldn't predict that with any computer program, Garry said. Nature usually is better at doing things than we can figure out with a computer these days. That's pretty good evidence that this virus did evolve to bind to human ACE-2 on its own. Nobody helped it. If somebody had designed it, they would have used a different solution.
I asked if there was any possibility some evil-genius person out there, with a different computer algorithm, could have come up with it. Like in the comic books? It doesnt seem likely, Garry said.
"This is a convincing argument," Millet confirmed. "SARS-CoV and SARS-CoV-2 do bind the same receptor but they do so in different ways that is most likely through an evolutionary process whereby each virus has 'figured out' different ways to do so...This goes against the notion that someone or a group would have intentionally used the SARS-CoV sequence to generate a new virus."
Additionally, if someone wanted to make a coronavirus, they would use another virus as a building block, Garry said. But the virus that is closest to SARS-CoV-2 is a bat virus that wasnt discovered until after the outbreak. There's no evidence from the SARS-CoV-2 genome that any other virus was used as a backbone to make something new.
Viruses mutate at a steady rate, and so as they spread, researchers can look at how many adaptations they've acquired and count back in time to figure out when it appeared. Co-author Andrew Rambaut, professor of Molecular Evolution at University of Edinburgh, did this, and found that SARS-CoV-2 sprung up in humans in either late November or early Decemberwhich makes sense given it was December 31 that Chinese authorities told the World Health Organization about the outbreak.
That's the "when," but it doesnt tell us where exactly it came from. In the SARS epidemic from the early 2000s, the virus transferred directly from a civet cat to humans. It didnt have to adapt, Garry said. It was already good to go. With MERS, it was a similar storythe same virus that infected camels got passed to humans.
SARS and MERS didnt transmit between people as well as the new coronavirus does. That could be because SARS-CoV-2 has adapted more to humansmeaning it didnt just jump from an animal, but first adapted to infect us better. I could be proven wrong tomorrow," Garry said. "Somebody could find an animal out there that has a virus that's identical to SARS-CoV-2. I don't think that's going to happen."
The closest virus to the new coronavirus is a bat virus, RaTG13, which is 96 percent similar. Yet its missing one crucial thing: its spike has a different receptor binding domain, not the defining one that SARS-CoV-2 has. Intriguingly, another recently discovered virus, from the pangolin, a scaly anteater, is less like SARS-CoV-2 overall, but does have a strongly similar receptor binding domain.
Garry said that because of this, he and his co-authors think its possible that SARS-CoV-2 is a recombinant virus, meaning its a combination of two different viruses that shared their genetic information. This is like a couple moving in together and combining their kitchen appliances. Suddenly they have access to tools they didnt beforea Vitamix and a food processor. A coronavirus might have been able to gain the enhanced receptor binding and then mutated further until genetic luck brought it the furin cleavage site.
What we dont know is the specifics of where or when this recombination and other mutation occurred. It could have happened while the virus was still in an animalthen, after the furin cleavage adaptation, it was able to jump into humans and spread rapidly afterwards. Another possibility is that a previous non-pathogenic version of the virus was circulating in people for some time before the mutation at the cleavage site occurred and it started spreading rapidly. What we can say is that it's more complicated than just a "Chinese" or "Wuhan" disease. It's a virus that has changed and mutated many times, possibly from different animal sources, or within our own bodies, and with genetic good fortune, happened upon the right adaptations to take hold.
We wont know the virus's origins for sure until we have more data, but the answer could be a predictor of whats to come. If SARS-CoV-2 achieved its adaptations in animals, there's more of a risk for future similar outbreaks. If it adapted while already in humans, it's less likely those same mutations will happen againjust based on probability. Either way, we learn more about the many ways viruses make it into our lives.
The significance is that now we know that there's a new way you can get a pathogenic coronavirus through recombination," Garry said. "Spread or passage doesn't have to be a direct jump from an animal."
Figuring out the origins of SARS-CoV-2 and how it works will be important the next time another new coronavirus emerges.
If we can understand what types of coronaviruseswith what types of featuresare in animals now, it would make it easier to look at a virus's genome sequence and determine where it got its features from, or how its spike might bind to our cells. One way to do this would be to start gathering information about the coronaviruses that are in many kinds of animals now. Bat coronaviruses, for example, are incredibly under-sampled, Garry said. We know that the diversity of coronaviruses in bats is a lot more than what we know about right now. Just figuring that out would be important.
Sign up for our newsletter to get the best of VICE delivered to your inbox daily.
Follow Shayla Love on Twitter.
Go here to read the rest:
Once and for All, the New Coronavirus Was Not Made in a Lab - VICE
- 001 F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 15th, 2010] [Originally Added On: April 15th, 2010]
- 002 F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 16th, 2010] [Originally Added On: April 16th, 2010]
- 003 GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 004 GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 005 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 006 GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 007 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 008 GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 016 The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 017 Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 018 Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 019 ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 020 GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 021 The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 022 Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 023 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 024 Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 025 India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 026 Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 027 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 028 Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 029 India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 030 Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 031 Harvard Medical Schools new automated safety surveillance system provides faster early warnings in the postmarket evaluation of medical device safety [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 032 SalesForce.com partner introduces CRM for clinical trial management on Force Platform [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 033 Widespread fraud in the Clinical Trial of Drugs is pervasive event in United States [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 034 Scott Stern Kellogg School of Management speaks about “New Drug Development: From Laboratory to Blockbuster to Generic,” [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 035 collaborative clinical trials management software for Central Laboratories [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 036 MNC Pharma tries to capture the $1.9 billion Indian OTC market by selling Drugs through India’s 170000 post offices [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 037 Clinical Trial and Pharmacovigilance process automation [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 038 Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 039 Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 040 trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 041 Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: December 17th, 2010] [Originally Added On: December 17th, 2010]
- 042 PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: December 17th, 2010] [Originally Added On: December 17th, 2010]
- 043 Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: December 23rd, 2010] [Originally Added On: December 23rd, 2010]
- 044 IBM Files Application to Patent The Patent [Last Updated On: January 9th, 2011] [Originally Added On: January 9th, 2011]
- 045 How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 046 Clinical Trial and Pharmacovigilance process automation [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 047 Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 048 Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 049 trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 050 Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 051 PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 052 Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 053 IBM Files Application to Patent The Patent [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 054 How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 055 AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 056 AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 057 Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 058 Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 059 Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 060 Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 061 Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 062 Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 063 Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 064 Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 065 Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- 068 Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- 069 Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- 070 Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- 071 One Way to Teach Your Boss About Social Media [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 072 “The Banks Can Do It, Why Can’t Hospitals?” [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 073 Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 074 Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 075 Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 076 Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 077 bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 079 privacy controlled social networking to connect patients with caregivers [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 080 SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]